AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.63
-0.14 (-2.43%)
At close: Oct 28, 2025, 4:00 PM EDT
5.62
-0.01 (-0.18%)
Pre-market: Oct 29, 2025, 4:47 AM EDT
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $17.08M in the quarter ending June 30, 2025, with 133.29% growth. This brings the company's revenue in the last twelve months to $32.88M, down -0.54% year-over-year. In the year 2024, AbCellera Biologics had annual revenue of $28.83M, down -24.17%.
Revenue (ttm)
$32.88M
Revenue Growth
-0.54%
P/S Ratio
50.80
Revenue / Employee
$55,161
Employees
596
Market Cap
1.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ABCL News
- 21 days ago - AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 - Business Wire
- 22 days ago - AbCellera Biologics: Entering Growth Phase After A Pause - Seeking Alpha
- 4 weeks ago - AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 6 weeks ago - AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer - Business Wire
- 2 months ago - AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 2 months ago - AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
- 2 months ago - AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Business Wire